Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate in Patient With Rare Tumor (Phase I Study)

NCT01046487 is registered in ClinicalTrials.gov with Centre Oscar Lambret as lead sponsor.

NCT NCT01046487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01046487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate in Patient With Rare Tumor (Phase I Study)
Lead sponsor
Centre Oscar Lambret
Phase
Phase 1
Overall status
Completed
Start date
February 9, 2009
Completion date
February 29, 2012
Enrollment
26 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cancer